|Videos|August 8, 2016

Strategies to Prevent Infection Transmission in Pediatric Healthcare Settings

Matt Linam, MD, MS, medical director of Infection Prevention at Arkansas Children’s Hospital, discusses how visitors can help prevent infection transmission in pediatric healthcare settings.

Matt Linam, MD, MS, medical director of Infection Prevention at Arkansas Children’s Hospital, discusses how visitors can help prevent infection transmission in pediatric healthcare settings.

Interview Transcript (slightly modified for readability).

“I think there [are] two key messages that I would want to send to parents and visitors of children [who] are hospitalized. The first is, hand hygiene really is the number one thing. Making sure that everyone, including themselves, do hand hygiene on the way into the room and when they leave the room, that’s really one of the number one strategies to prevent transmission of infection and keep their child [who’s] in the hospital safe.

The other is making sure that no one comes to visit that hospitalized child if they may have [infectious disease] symptoms; that’s a way that parents can really help us out, [by] discouraging other family members or visitors from coming to visit if they may be symptomatic.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.